Connor Clark & Lunn Investment Management Ltd. Sells 18,530 Shares of Harrow, Inc. (NASDAQ:HROW)

Connor Clark & Lunn Investment Management Ltd. lessened its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 14.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 111,894 shares of the company's stock after selling 18,530 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.31% of Harrow worth $3,754,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. First Turn Management LLC bought a new stake in shares of Harrow in the 3rd quarter worth $14,683,000. JPMorgan Chase & Co. grew its stake in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock worth $10,717,000 after acquiring an additional 194,480 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Harrow by 195.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock worth $11,313,000 after acquiring an additional 166,602 shares in the last quarter. Braidwell LP grew its stake in shares of Harrow by 47.9% in the 3rd quarter. Braidwell LP now owns 439,638 shares of the company's stock worth $19,766,000 after acquiring an additional 142,450 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Harrow by 3,015.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 79,974 shares of the company's stock worth $3,596,000 after acquiring an additional 77,407 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

Remove Ads

Harrow Price Performance

Shares of Harrow stock traded up $0.32 on Friday, reaching $28.41. The stock had a trading volume of 625,211 shares, compared to its average volume of 497,169. Harrow, Inc. has a 1 year low of $9.86 and a 1 year high of $59.23. The company has a market cap of $1.01 billion, a P/E ratio of -30.22 and a beta of 0.69. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The business's 50 day moving average is $29.67 and its two-hundred day moving average is $38.48.

Analyst Upgrades and Downgrades

HROW has been the subject of several recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $57.00 target price on shares of Harrow in a research note on Tuesday. B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.